What's Happening?
Verily, a company originally launched as a Google X project and later a subsidiary of Alphabet, has raised $300 million to further its work in artificial intelligence and precision health. This funding round was led by Series X Capital, with Alphabet remaining
a significant minority investor. Verily has transitioned from an LLC to a corporation, now known as Verily Health, marking its independence from Alphabet's direct control. The company aims to enhance its AI health platform to improve patient outcomes and reduce healthcare delivery costs. Verily has developed a precision health platform, Verily Pre, and a consumer health app, Verily Me, which provides personalized care recommendations. The company is also expanding its AI models and agents for research and care workflows, including programs like Lightpath for chronic disease management and Sightline for infectious disease detection.
Why It's Important?
Verily's transition to an independent company and its significant investment in AI and precision health reflect a broader trend in the healthcare industry towards personalized medicine and data-driven care solutions. By focusing on AI, Verily aims to address longstanding challenges in healthcare, such as improving patient outcomes and lowering costs. The involvement of major investors like Alphabet, UCHealth, and the University of Colorado Anschutz highlights the potential impact of Verily's innovations on the healthcare sector. The company's efforts to integrate AI into healthcare could lead to more efficient and effective treatments, benefiting patients and healthcare providers alike. This move also positions Verily as a key player in the growing field of digital health and precision medicine.
What's Next?
Verily plans to use the $300 million investment to expand its AI and precision health capabilities, including the development of new AI agents and commercial opportunities. The company is collaborating with partners like Samsung and Salesforce to integrate sensor data and improve data analysis in healthcare. Verily is also working with Nvidia to enhance its AI technology stack, which could accelerate the development of AI models for clinical care and research. As Verily continues to grow its commercial partnerships and refine its focus on precision medicine, it is likely to play a significant role in shaping the future of healthcare technology.
